Vascular Parkinsonism Market

Vascular Parkinsonism Market Size and Share Forecast Outlook 2025 to 2035

The vascular parkinsonism market is forecasted to grow from USD 319.5 million in 2025 to USD 538.1 million by 2035, at a CAGR of 6.20% during the forecast period. The growth is being driven by the increasing incidence of vascular parkinson's disease and the rising demand for advanced therapeutic options.

Quick Stats in the Vascular Parkinsonism Market

• Market Value (2025): USD 319.5 million
• Forecast Value (2035): USD 538.1 million
• Forecast CAGR: 6.20%
• Leading Segment in 2025: Dopaminergic Agents (~42.5% share)
• Key Growth Region: South Asia
• Top Key Players: Novartis, AbbVie Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Roche Holding AG

Vascular parkinsonism, caused by damage to blood vessels in the brain, is characterized by motor and non-motor symptoms. The industry is being influenced by growing awareness of vascular parkinson's disease and advancements in drug development for neurodegenerative diseases.

Vascular parkinsonism has been regarded as a niche indication within the broader neurology industry. In 2025, nearly 1.2% of the Parkinson’s therapeutics industry is expected to be captured by its treatment segment. The share within the larger movement disorders treatment industry is projected to decline to 0.6%. In the neurodegenerative disease therapeutics segment, its share is estimated at 0.35%, and in the central nervous system industry, it drops further to 0.05%.

Around 0.4% of the cerebrovascular therapies industry is anticipated to be attributed to vascular parkinsonism. This limited share is influenced by diagnostic limitations, a scarcity of approved drugs, and ongoing reliance on levodopa. Expansion is expected as screening improves and neuroprotective therapies advance.

ValtteriKaasinen, Professor of Neurology at the University of Turku and principal investigator of the study, stated on April 7, 2025, “Notably, a majority of these diagnostic changes occur within the first two years of diagnosis, which emphasises the challenges and uncertainty clinicians face in diagnosing Parkinson's disease accurately.”

A Phase 1 clinical trial at Mass General Brigham is being conducted to examine a novel treatment approach for Parkinson’s disease. In this trial, patients’ stem cells are being reprogrammed to replace dopamine-producing cells lost due to the disease. Three patients have been enrolled and treated in this first-of-its-kind autologous stem cell transplant trial. A total of six participants will be followed for 12 months to monitor the safety and effectiveness of the procedure

Analyzing Vascular Parkinsonism Market by Top Investment Segments

Strong growth is expected in the vascular parkinsonism market, driven by dopaminergic agents, oral administration routes, and retail pharmacy chains. These factors are ensuring wider accessibility and effective treatment options.

Dopaminergic Agents Predicted to Dominate Vascular Parkinson's Disease Treatment

Dopaminergic agents are expected to dominate the market, holding a 42.5% share in 2025.

• Dopamine levels in the brain are increased using specific agents to address the underlying neurological deficit in Parkinson’s disease and vascular parkinsonism. These drugs are widely prescribed to manage the motor symptoms. Associated with conditions including tremors, stiffness, and bradykinesia.
• Key companies like AbbVie, with its prominent product Sinemet, and Merck, with its broader dopaminergic drug portfolio, are major contributors to the availability of these treatments.
• The rising diagnosis rates of vascular parkinsonism, along with increased awareness and access to treatments, are driving industry growth. As more treatment options become available, dopaminergic agents are expected to remain at the forefront of managing vascular parkinson's disease symptoms.

Oral Medications to Be the Leading Choice in Vascular Parkinson's Disease Treatment

Oral medication is expected to dominate the route of administration segment, with an 81.4% share in 2025.

• Oral medications are favored due to their convenience and ease of administration, making them the preferred choice for long-term treatment regimens. Companies like GlaxoSmithKline with their dopamine agonist product Requip and AbbVie’s Sinemet, an oral levodopa/carbidopa combination, are widely used to treat vascular parkinson's disease
• Oral drugs are increasingly prescribed because they offer effective symptom relief. They require minimal intervention, making them suitable for use at home. As more patients opt for self-management of their condition, oral medications will continue to drive the growth of the industry.

Retail Pharmacy Chains Expected to Lead Sales in Vascular Parkinsonism Drugs

Retail pharmacy chains are projected to hold 42% of the share by 2025.

• Accessible treatment options are provided through these channels, ensuring that prescribed dopaminergic agents can be conveniently purchased by patients.
• Companies such as Walgreens and CVS Health are leading the retail pharmacy sector, offering various Parkinson's treatment options through brick-and-mortar stores and online platforms.
• The growing trend of patient-centered care, where individuals prefer easy access to medication, especially for chronic conditions like vascular parkinsonism, is supporting the dominance of retail pharmacies.
• Improved online pharmacies and home delivery services are contributing to the widespread availability of drugs.

Top Vascular Parkinsonism Market Dynamics

The vascular parkinsonism market is being driven by the increasing prevalence of cerebrovascular diseases and advancements in diagnostic imaging. However, challenges such as limited awareness and the complexity of distinguishing it from idiopathic Parkinson's disease are hindering industry growth.

Increasing prevalence of cerebrovascular diseases is driving industry growth

The rising incidence of cerebrovascular diseases, including strokes and small vessel disease, is significantly contributing to the demand for vascular parkinson's disease therapies.

• Ischemic lesions in the brain, particularly in areas involved in motor control, increase the risk of developing vascular parkinsonism.
• With the aging global population, the prevalence of cerebrovascular events is expected to rise, further elevating the incidence of vascular parkinsonism.
• The growing burden is prompting healthcare systems to adopt advanced diagnostic and therapeutic interventions, driving the demand for vascular parkinson's disease treatments.

Advancements in diagnostic imaging are enhancing early detection

Advancements in neuroimaging techniques, such as high-resolution MRI and PET scans, are improving the early detection and accurate diagnosis of vascular parkinsonism.

• Imaging modalities allow for the identification of subtle ischemic changes in the brain, facilitating differentiation from other forms of parkinsonism.
• Early and precise diagnosis is crucial for initiating appropriate treatment strategies, which can potentially slow disease progression and improve patient outcomes.
• The enhanced diagnostic capabilities are contributing to the increased adoption of therapies, thereby supporting industry growth.

Analyzing Top Countries Synthesizing, Distributing, and Generating Demand for Vascular Parkinsonism Treatment

Country	CAGR (2025 to 2035)
United States	5.1%
Germany	4.7%
China	7.3%
Japan	3.9%
India	8.4%

The Vascular Parkinsonism industry is expected to grow at a global CAGR of 6.20% from 2025 to 2035, with varying growth rates seen in key countries. The highest growth rate of 8.4% is expected in India, driven by an expanding healthcare infrastructure and rising demand for neurological treatments. A 7.3% growth rate is expected in China, fueled by a large population and an increasing focus on healthcare innovation.

Moderate growth of 5.1% is anticipated in the United States, as the industry remains stable with consistent demand for existing treatments. Slower growth of 4.7% is projected for Germany, while Japan is expected to experience the lowest growth at 3.9%, due to an aging population and slower adoption of new treatments. Emerging countries like India and China are expected to drive the majority of the growth, while developed industry are expected to remain stable but less dynamic.

In-depth Analysis of Vascular Parkinsonism Market in India

India is expected to grow at an 8.4% CAGR through 2035, leading the vascular parkinson's disease treatment industry among major countries, particularly in the BRICS group. The demand is supported by an aging population and increasing healthcare infrastructure. Industry expansion is driven by the rising incidence of cerebrovascular diseases, as well as growing awareness of vascular parkinson's diseaseas a distinct neurodegenerative disorder. The industry growth is being accelerated by government healthcare initiatives and increasing access to affordable medical treatments.

• Rising incidence of cerebrovascular diseases, including strokes, is contributing to demand.
• Increased focus on early diagnosis and advanced treatments is being observed.
• Growing healthcare infrastructure and awareness programs are driving industry growth.

Sales Analysis of Vascular Parkinsonism Market in the United States

The USA market is projected to grow at a 5.1% CAGR, reflecting steady demand for vascular parkinson's disease treatments, particularly within the OECD group. Growth is being driven by the adoption of advanced diagnostic technologies, including neuroimaging, and the aging baby boomer population. Despite the industry remaining niche, increased diagnosis and treatment adoption are being supported by government funding and the expansion of telehealth services. Significant R&D investments are being made to improve therapeutic outcomes for patients.

• Advanced diagnostic technologies are being widely adopted.
• Increased focus on personalized treatment options is contributing to growth.
• Government and insurance support are enabling easier treatment access.

Demand Outlook for Vascular Parkinsonism Market in Germany

Germany’s market for Vascular Parkinsonism is expected to grow at a 4.7% CAGR by 2035, contributing to the growth of the EU market. The development and adoption of effective treatments are being facilitated by the country’s advanced healthcare system and robust research capabilities. Long-term care solutions are being emphasized by healthcare policies, benefiting patients. Industry expansion is being supported by an aging population and rising stroke incidence, with neuroprotective treatments being increasingly integrated into care strategies.

• Research and clinical trials are being strongly focused on.
• Rising incidence of strokes among the elderly is contributing to industry growth.
• Strong healthcare infrastructure is enabling easier treatment access.

Opportunity Analysis of Vascular Parkinsonism Market in China

China is expected to grow at a 7.3% CAGR through 2035, leading the BRICS group in vascular parkinson's disease industry growth. The adoption of advanced diagnostic methods, along with greater awareness of vascular Parkinsonism, is propelling the industry. Industry development is being supported by China’s growing focus on improving healthcare systems and expanding access to specialized treatments. Government initiatives to address neurodegenerative diseases are expected to further accelerate industry growth.

• Rising stroke incidence and an aging population are driving demand.
• Early diagnostic methods are being increasingly adopted.
• Government-led healthcare innovation is supporting industry development.

Demand Analysis for Vascular Parkinsonism Market in Japan

The sales in Japan for Vascular Parkinsonism is projected to grow at a 3.9% CAGR through 2035, contributing to the growth of the OECD region. The demand for neurodegenerative treatments, including therapies, is being driven by the aging population. Industry growth is being supported by Japan’s emphasis on precision medicine, neuroimaging, and clinical research. Although vascular parkinson's disease remains a specialized focus, steady growth is being ensured by Japan's leadership in pharmaceutical development and healthcare technology.

• Precision medicine and diagnostic tools are being highly emphasized.
• Increased demand is being contributed to by the aging population.
• Clinical research is supporting industry development.

Vascular Parkinsonism Market Growth Outlook in Germany

Germany’s Vascular Parkinsonism demand is projected to grow at a steady 4.7% CAGR through 2035, contributing significantly to the EU market. The solid foundation for developing effective treatments is being provided by the country’s efficient healthcare system. The growth of the industry is being driven by focused clinical trials and the integration of new diagnostic technologies, such as neuroimaging and biomarkers. Additionally, the aging population and rising cases of cerebrovascular diseases are contributing to industry expansion.

• New diagnostic technologies are being integrated into treatment strategies.
• Research funding and clinical trials are being increased.
• Rising prevalence of cerebrovascular diseases among the elderly is contributing to growth.

Leading Players in the Vascular Parkinsonism Market

The Parkinson's disease treatment industry features a semi-consolidated competitive landscape, segmented into dominant players, key players, and emerging firms. Dominant players such as AbbVie, Merck & Co., and GlaxoSmithKline hold leading positions, supported by strong R&D pipelines, branded therapies like levodopa combinations, and global commercialization strategies. Key players including Novartis, Teva, and UCB focus on diversified neurology portfolios and next-generation dopamine agonists.

Emerging players such as Acadia Pharmaceuticals, Amneal, and Sun Pharma are expanding their presence through generics, novel delivery systems, and niche indications like non-motor symptoms and advanced-stage management, enhancing accessibility and innovation in Parkinson’s disease therapeutics.

Recent Vascular Parkinsonism Industry News

• In April 2025, BlueRock Therapeutics, a subsidiary of Bayer AG, announced the publication of 18-month data from its Phase 1 clinical trial for bemdaneprocel, an investigational cell therapy for Parkinson’s disease, in Nature. The study demonstrated sustained neuron cell engraftment and no serious adverse events following immunosuppression discontinuation. A Phase 3 trial is expected to begin in the first half of 2025.
• In August 2024,AbbVie completed the acquisition of Cerevel Therapeutics, gaining access to tavapadon, a selective dopamine D1/D5 receptor partial agonist for Parkinson’s disease. The drug is expected to launch in the USA in 2025.

Key Players in the Vascular Parkinsonism Market

• Novartis
• AbbVie Inc.
• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.
• Roche Holding AG
• GlaxoSmithKline (GSK)
• BoehringerIngelheim
• Sanofi
• Sun Pharmaceutical Industries Ltd.

Research Coverage and Scope Summary

Report Attributes	Details
Market Size (2025)	USD 319.5 million
Projected Market Size (2035)	USD 538.1 million
CAGR (2025 to 2035)	6.20%
Base Year for Estimation	2024
Historical Period	2020 to 2024
Projections Period	2025 to 2035
Quantitative Units	USD million for value and million units for volume
Drug Classes Analyzed (Segment 1)	Dopaminergic Agents, Antithrombotic Agents, Cognitive Enhancers, Antihypertensive Agents, Muscle Relaxants
Routes of Administration Analyzed (Segment 2)	Oral, Injectable, Dermal Patches
Sales Channels Analyzed (Segment 3)	Hospitals, Neurology Clinics, Retail Pharmacy Chains, Mail-Order Pharmacies
Regions Covered	North America, Western Europe, East Asia, South Asia
Countries Covered	United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, India, Japan, South Korea, Australia, Brazil, Mexico, Argentina, Saudi Arabia, UAE, South Africa
Key Players	Novartis, AbbVie Inc., Teva Pharmaceutical, Pfizer Inc., Roche Holding AG, GlaxoSmithKline, Boehringer Ingelheim, Sanofi, Sun Pharmaceutical
Additional Attributes	Dollar sales, share by drug class and route of administration, increasing demand for cognitive enhancers and antithrombotic agents, regional market growth in neurology clinics, advancements in muscle relaxants and injectable formulations

Vascular Parkinsonism Market Analyzed by Key Investment Segments

By Drug Class:

The industry is segmented into dopaminergic agents, antithrombotic agents, cognitive enhancers, antihypertensive agents, and muscle relaxants.

By Route of Administration:

The industry includes oral, injectable, and dermal patches.

By Sales Channel:

The industry covers hospitals, neurology clinics, retail pharmacy chains, and mail-order pharmacies.

By Region:

The industry spans North America, Western Europe, East Asia, and South Asia.